Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ)

Duncan, Polly, Murphy, Mairead, Man, Mei-See ORCID: https://orcid.org/0000-0003-4948-5670, Chaplin, Katherine, Gaunt, Daisy and Salisbury, Chris (2018) Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ). BMJ Open, 8 (4). ISSN 2044-6055

Preview

PDF (Published_Version) - Published Version Available under License Creative Commons Attribution. Download (285kB) | Preview

Abstract

OBJECTIVE: To develop and validate a new scale to assess treatment burden (the effort of looking after one's health) for patients with multimorbidity. DESIGN: Mixed-methods. SETTING: UK primary care. PARTICIPANTS: Content of the Multimorbidity Treatment Burden Questionnaire (MTBQ) was based on a literature review and views from a patient and public involvement group. Face validity was assessed through cognitive interviews. The scale was piloted and the final version was tested in 1546 adults with multimorbidity (mean age 71 years) who took part in the 3D Study, a cluster randomised controlled trial. For each question, we examined the proportion of missing data and the distribution of responses. Factor analysis, Cronbach's alpha, Spearman's rank correlations and longitudinal regression assessed dimensional structure, internal consistency reliability, construct validity and responsiveness, respectively. We assessed interpretability by grouping the global MTBQ scores into zero and tertiles (>0) and comparing participant characteristics across these categories. RESULTS: Cognitive interviews found good acceptability and content validity. Factor analysis supported a one-factor solution. Cronbach's alpha was 0.83, indicating internal consistency reliability. The MTBQ score had a positive association with a comparator treatment burden scale (rs 0.58, P<0.0001) and with self-reported disease burden (rs 0.43, P<0.0001), and a negative association with quality of life (rs-0.36, P<0.0001) and self-rated health (rs-0.36, P<0.0001). Female participants, younger participants and participants with mental health conditions were more likely to have high treatment burden scores. Changes in MTBQ score over 9-month follow-up were associated, as expected, with changes in measures of quality of life (EuroQol five dimensions, five level questionnaire) and patient-centred care (Patient Assessment of Chronic Illness Care). CONCLUSION: The MTBQ is a 10-item measure of treatment burden for patients with multimorbidity that has demonstrated good content validity, construct validity, reliability and responsiveness. It is a useful research tool for assessing the impact of interventions on treatment burden. TRIAL REGISTRATION NUMBER: ISRCTN06180958.

Item Type:	Article
Additional Information:	© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Uncontrolled Keywords:	aged,cost of illness,female,health status indicators,humans,male,middle aged,multimorbidity,pilot projects,psychometrics,quality of life,randomized controlled trials as topic,reproducibility of results,self-management,surveys and questionnaires,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Depositing User:	LivePure Connector
Date Deposited:	28 Jan 2020 03:54
Last Modified:	01 Oct 2024 01:50
URI:	https://ueaeprints.uea.ac.uk/id/eprint/73842
DOI:	10.1136/bmjopen-2017-019413

Downloads

Actions (login required)

View Item